Related Experiment Video

Updated: May 9, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Genistein down-regulates miR-223 expression in pancreatic cancer cells

Jia Ma1, Long Cheng, Hao Liu

  • 1Department of Biochemistry and Molecular Biology, Bengbu Medical College, Anhui, 233030, China.

Current Drug Targets
|July 10, 2013
PubMed

Insights

Genistein, a natural compound, inhibits pancreatic cancer (PC) by down-regulating miR-223. This leads to reduced cancer cell growth and invasion, offering a potential new strategy for PC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Genistein exhibits anti-tumor properties in various cancers, but its precise molecular mechanisms in pancreatic cancer (PC) remain unclear.
  • MicroRNAs (miRNAs) are crucial regulators of tumor development, making them potential therapeutic targets for cancer treatment.
  • Onco-miR-223 has been implicated in promoting cancer progression.

Purpose of the Study:

  • To investigate if genistein can down-regulate onco-miR-223 in pancreatic cancer cells.
  • To determine the effects of miR-223 down-regulation on PC cell growth, invasion, and apoptosis.
  • To elucidate the role of miR-223 in genistein's anti-cancer activity.

Main Methods:

  • Genistein treatment of pancreatic cancer cells.
  • Quantitative real-time PCR (qRT-PCR) to measure miR-223 and Fbw7 expression.
  • Cell proliferation assays.
  • Apoptosis assays.
  • Cell invasion assays.

Main Results:

  • Genistein treatment significantly inhibited miR-223 expression in PC cells.
  • Genistein treatment led to the up-regulation of Fbw7, a known target of miR-223.
  • Down-regulation of miR-223 suppressed PC cell growth and invasion.
  • Down-regulation of miR-223 induced apoptosis in PC cells.

Conclusions:

  • Genistein exerts anti-tumor effects in pancreatic cancer partly by down-regulating miR-223.
  • Targeting miR-223 represents a potential therapeutic strategy for pancreatic cancer.
  • This study highlights the role of miRNAs in mediating the effects of natural compounds like genistein.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...